AiXin Life International, Inc (AIXN) Fair Value & Analysis
Consumer Defensive · US · Market cap $8.0M
Fair value as of: Jun 23, 2026
Analysis
AiXin Life International, Inc (AIXN) currently trades at $0.3200, while our model-based Fair Value estimate is $0.0700 — implying the stock looks roughly 78.1% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
AiXin Life International, Inc. develops, manufactures, markets, and sells healthcare, nutritional products, and wellness supplements in the People's Republic of China. It operates through Direct Sales, Pharmacy, Hotel, and Manufacture and Sale segments. The company provides herbs, greens, and traditional Chinese remedies; and functional products, such as weight management tools, probiotics, and foods and drinks; and rhino king, colostrum powder derived from goat's milk, tong li ke, gammaoling granules, amoxicillin capsules, loratadine tablets, and fuyang granules. It also engages in hotel business. The company provides products manufactured by the company and purchased from third parties, as well as marketing and distribution services to other manufacturers and suppliers of healthcare products. It sells its products through company-owned offices open to clients, pharmacies, direct marketing, e-commerce, exhibition events, conferences, and person-to-person marketing. AiXin Life Inter…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is AiXin Life International, Inc (AIXN) undervalued?
What is the fair value of AIXN?
What is the quality score of AIXN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.